Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma

Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:March 2016
End Date:March 2019

Use our guide to learn which trials are right for you!

Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

This research trial studies clinical factors and gene expression analysis for prognosis in
tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary
effusion lymphoma. Gathering health information over time and studying samples of tissue from
patients in the laboratory may help doctors learn about the prognosis of patients with
AIDS-related primary effusion lymphoma.


I. Identify baseline clinical characteristics and treatment strategies in patients with
AIDS-associated primary effusion lymphoma (PEL) that correlate with long-term survival (>= 2
years). (Primary clinical objective) II. Identify differentially expressed genes in PEL that
are associated with long-term survival (>= 2 years). (Primary genomic objective)


Medical chart review is performed and patient information is collected regarding human
immunodeficiency virus human immunodeficiency virus (HIV)/AIDS medical history, staging of
AIDS related malignancy, and type of treatment. Previously collected tissue samples are
analyzed via ribonucleic acid (RNA) sequencing and microarray.

Inclusion Criteria:

- Patients diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or
after January 1, 1998 on whom survival status at 2 years post PEL diagnosis is

- Participants may be enrolled to either or both the clinical or genomic portions of the

- The minimum data required to be able to include a subject for analysis of clinical
prognostic factors are:

- HIV status, and for HIV subjects include cluster of differentiation (CD)4 count,
HIV viral load closest to time of diagnosis

- Age at PEL diagnosis

- Gender

- Stage at diagnosis

- Treatment of PEL

- Response to treatment

- Survival status at 2 years

- Pathology slides (or paraffin block) for central review

- The minimum data required to be able to include a subject for analysis of genomic
prognostic factors are:

- Availability of a pathologic specimen of PEL that will be submitted for genomic

- Survival status at 2 years

Exclusion Criteria:

- Patients who do not fulfill the criteria as listed above are ineligible
We found this trial at
Miami, Florida 33124
(305) 284-2211
Principal Investigator: Juan C Ramos, MD
Phone: 305-243-9448
University of Miami A private research university with more than 15,000 students from around the...
Miami, FL
Click here to add this to my saved trials
9911 W Pico Blvd # 980
Los Angeles, California 90095
Principal Investigator: Ronald Mitsuyasu, MD
Phone: 310-557-9062
Los Angeles, CA
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Paul Rubinstein, MD
Phone: 312-864-7277
Chicago, IL
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Erin G. Reid, MD
Phone: 858-822-6271
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
La Jolla, CA
Click here to add this to my saved trials
Seattle, Washington 98101
(888) 862-2737
Principal Investigator: David Aboulafia, MD
Phone: 206-342-6928
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
Seattle, WA
Click here to add this to my saved trials